NG004 not checked

NovaGo Therapeutics AG

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Acute Spinal Cord Injury (SCI) (2 trials), Spinal Cord Diseases (2 trials), Central Nervous System Diseases, Nervous System Diseases, Trauma, Nervous System, Spinal Cord Injuries (SCI), Wounds and Injuries, Spinal Cord Injuries and 1 more
Main trialPhase 1
“This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004. The trial consists of Part A (the dose escalation) and Part B (the PK-confirmation at 2 dose levels from Part A).”In the company’s words, NCT06817577 on ClinicalTrials.gov

Other drugs for Acute Spinal Cord Injury (SCI)

All 3 drugs for Acute Spinal Cord Injury (SCI)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Mar 2027 NG004 in Spinal Cord Injury Patients
Phase 1Recruiting Jul 2029 NG004 in Incomplete Spinal Cord Injury Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow NG004

Following is part of Solo: you see every change to NG004 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in